Logo image
CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa
Journal article   Open access   Peer reviewed

CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa

K A Cunningham, A J Carey, N Lycke, Peter Timms and K W Beagley
Journal of Reproductive Immunology, Vol.81(1), pp.34-38
2009
pdf
PDF - Author's Accepted Version (Open Access)177.99 kBDownloadView
Accepted VersionPDF - Author Accepted Version (Open Access)CC BY-NC-ND V4.0 Open Access
url
https://doi.org/10.1016/j.jri.2009.04.002View
Published Version

Abstract

Chlamydia CTA1-DD mucosal adjuvant vaccine
Chlamydia trachomatis is a significant human pathogen with potentially severe disease sequelae in the genital tract, including infertility. A successful vaccine will need to effectively target immunity to the genital mucosa. Intranasal immunisation with cholera toxin (CT) can target immunity to the genital tract, but has the potential to cause neurological side effects. CTA1-DD is a non-toxic potent mucosal adjuvant which combines the enzymatic properties of CT, with a B cell targeting moiety. Here, we demonstrate that intranasal immunisation with CTA1-DD and chlamydial Major Outer Membrane Protein (MOMP) results in the induction of neutralising systemic and mucosal antibodies, and reduces the level of chlamydial shedding following intravaginal challenge with Chlamydia muridarum. Thus, CTA1-DD is an effective adjuvant for vaccine development against Chlamydia trachomatis, and possibly also a range of other genital pathogens. © 2009 Elsevier Ireland Ltd. All rights reserved.

Details

Metrics

191 File views/ downloads
699 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Web Of Science research areas
Immunology
Obstetrics & Gynecology
Reproductive Biology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Logo image